Compare Cytokinetics Inc (CYTK) vs FirstEnergy Corp. (FE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs FirstEnergy Corp. — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while FirstEnergy Corp. trades at $46.86 (market cap $27.06B). The key difference: FirstEnergy Corp. is far larger — about 2.5× Cytokinetics Inc's market cap, and FirstEnergy Corp. pays a 3.98% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | FE | |
|---|---|---|
Market Cap | $10.78B | $27.06B |
Sector | Technology | Utilities |
52-Week High | $87.26 | $51.91 |
52-Week Low | $33.23 | $42.83 |
Enterprise Value | $10.88B | $55.98B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
FirstEnergy (FE) trades at $47.47, up 0.2% today, with a bearish technical signal from indicators like the 6-day RSI at 11.10 and ADX signaling strong trend strength. The company reported Q2 2026 EPS of $0.50, slightly missing expectations, but revenue growth is supported by data center demand and a $36 billion grid investment plan. Analyst consensus is a Buy with a $52.67 price target, though technicals suggest near-term pressure.
The outlook is mixed: strong fundamentals with rising revenue and stable margins offer long-term value, but technical bearishness and high debt levels pose risks. Investment opportunity lies in grid expansion and data center growth, while risks include execution challenges and interest rate sensitivity. The stock presents a defensive play with growth potential amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →
